Mary Kay Koenig, MD
Neurology with Special Qualifications in Child Neurology · Houston, TXNPI 1881895993
Payments from drug & device makers
Across 517 payments — averaging $2548.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Immedica Pharma US, Inc.$409K
- PTC Therapeutics, Inc.$362K
- Astellas Pharma Inc$208K
- Jazz Pharmaceuticals Inc.$189K
- Novartis$73K
- Pfizer$42K
- plus $34K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Immedica Pharma US, Inc. | 71 | $409,498 |
| PTC Therapeutics, Inc. | 76 | $361,810 |
| Astellas Pharma Inc | 38 | $208,223 |
| Jazz Pharmaceuticals Inc. | 106 | $188,811 |
| Novartis | 103 | $72,676 |
| Pfizer | 4 | $42,286 |
| Acadia Pharmaceuticals Inc | 15 | $12,661 |
| Greenwich Biosciences, Inc. | 21 | $8,371 |
| Mallinckrodt Enterprises LLC | 2 | $4,500 |
| UCB SA | 3 | $3,200 |
| H. Lundbeck A S | 5 | $2,084 |
| UCB, Inc. | 32 | $1,194 |
| Zogenix Inc. | 1 | $1,000 |
| Vertex | 1 | $517 |
| Biogen | 6 | $159 |
| Upsher-smith Laboratories LLC | 5 | $135 |
| Eisai Inc. | 6 | $128 |
| Sunovion Pharmaceuticals Inc. | 7 | $125 |
| Ultragenyx Pharmaceutical Inc. | 1 | $122 |
| Neurocrine Biosciences, Inc. | 3 | $81 |
| SK Life Science, Inc. | 2 | $53 |
| Pyros Pharmaceuticals, Inc. | 1 | $30 |
| Bioventus LLC | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Aprecia Pharmaceuticals, LLC | 1 | $22 |
| Neurelis, Inc. | 1 | $19 |
| Livanova USA, Inc. | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $14 |
| Aucta Pharmaceuticals, Inc. | 2 | $3 |
How this compares
$1,317,784 in reported general payments places this provider in the 95th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
See all neurology with special qualifications in child neurology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology with special qualifications in child neurology in Houston
- Huda ZoghbiHouston$8.3M
- Davut PehlivanHouston$1M
- Timothy LotzeHouston$806K
- Nikita ShuklaHouston$344K
- Gary ClarkHouston$340K
- Nivedita ThakurHouston$311K
- Gretchen von AllmenHouston$269K
- Shade MoodyHouston$260K
- Sarah WilsonHouston$139K
- Shelley VarnadoHouston$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.